When: Confirmed daily close above $378.87 (50 SMA) with SMA slope flattening (not still declining) and volume >2.5M shares, sustained 2 consecutive sessions; OR backup: Sustained MACD positive crossover for 5+ sessions with histogram expanding above zero

Then: NOT triggered; stop trails to $348 (below prior rejection zone)

SELL (refined to 50% benchmark weight via staged sales into strength, with escalation to 40% if price breaks July lows)

• $5.2 billion net cash position with zero long-term debt and 28.4% net margins provides fundamental floor against capitulation
• RSI at 37 (not capitulated below 25) and price below lower Bollinger band at $348 creates mean-reversion squeeze risk toward 50 SMA at $378.87 or 200 SMA at $461.77
• Trader's plan to reduce to 50% benchmark weight via staged sales into strength is directionally correct but needs tighter stop discipline
• Abort level for sell program is daily close above 50 SMA at $378.87; plan needs clarification on whether this suspends staged sales or locks core position
• Terminal weight should flex to 40% if price breaks lower Bollinger band at $348 and prints below $328.57 July 23 swing low on elevated volume
• Re-risking trigger: Q3 earnings in late October showing procedure-volume reacceleration and Ion traction, OR sustained reclaim of 50 SMA with RSI clearing 50 and MACD histogram turning positive
• Aggressive Analyst misreads fortress balance sheet; equity in cash-generative healthcare franchise has better downside floor than capital-hungry growth names
• Neutral Analyst confuses 'when to add' with 'what to do with current position'—holding full weight through confirmed death-cross regime with deepening MACD histogram at -2.51 is effectively long a broken chart

→ vs aggressive: Full liquidation exposes firm to significant mean-reversion risk; August 11 precedent shows price ripped from low $330s to $402 in two weeks on failed bounce; equity with $5.2B net cash and zero debt rarely revisits capitulation lows once establishing higher base

→ vs neutral: HOLD at full benchmark weight through confirmed death-cross with price below all moving averages, MACD histogram at -2.51 actively deepening, and volume confirming distribution is not neutral—it is effectively long a broken chart; waiting to reclaim 50 SMA at $378.87 means giving back another 5–10% of NAV

Support SELL with refinements: reduce to 50% benchmark weight via staged sales into strength at $365 and $378, defensive stop on core at $340 on daily close basis, pre-commit re-weighting framework to Q3 earnings and 50 SMA reclaim.

• Aggressive Analyst's multiple compression thesis challenged—fortress balance sheet, $5.2B net cash, 28% net margin, and 17% ROE provide fundamentally different floor than capital-hungry names
• Confirmation-based systems (50 SMA reclaim, MACD crossover, positive histogram) are path-dependent losers in choppy environments—buying at $380 or higher gives back the entire 7% being protected
• Conservative Analyst's mean-reversion call is premature—23% below 200 SMA at $461.77, 6.8% below 50 SMA at $378.87, and mean reversion can take quarters or years
• August 11 rally from $332 to $402 was 21% move in 13 trading days on single failed bounce—shows full exit risk if re-rating occurs while fully out
• Absence of retail sentiment unusual—zero Reddit posts across wallstreetbets, stocks, and investing in 7 days means thin bid and failed rallies
• Path of least resistance is lower—below lower Bollinger band, MACD at lowest reading since July, breakdown on September 8 with above-average volume
• Execution framework refined: first tranche at $365 10 EMA zone with RSI 40-50; second tranche at $378 50 SMA with RSI above 50 on daily close
• Defensive stop on remaining 50% core position at $340 (July 23 intraday low, approximately one ATR below current price)
• Re-risking framework anchored to two binary events: (1) Q3 earnings late October with procedure volume reacceleration, Ion platform strength, and forward guidance reaffirmation; (2) three consecutive daily closes above $378.87 50 SMA with RSI above 50 and MACD histogram positive
• Decision is risk management on how much exposure to carry, not directional bet on ISRG going up or down

→ vs aggressive: Asymmetric thesis requires knowing where multiple compression stops—20x is not necessarily the floor for a fortress balance sheet franchise with recurring revenue and 28% net margin

→ vs conservative: Mean-reversion call is same anchoring bias being criticized—23% below 200 SMA and 6.8% below 50 SMA does not make reversion imminent; triggers are minimum 6 weeks away

→ vs conservative: Wait-and-see instinct on $328 hold is the same trap being criticized—must act on current tape signals, not hoped-for future signals

→ vs conservative: Failed to weigh absence of retail sentiment (zero Reddit posts in 7 days)—thin bid and failed rallies until buy-the-dip crowd arrives